NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy

被引:1
|
作者
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [1 ]
Tereshko, Yan [1 ]
Gigli, Gian Luigi [3 ]
Pucillo, Carlo Ennio [4 ]
Valente, Mariarosaria [1 ,3 ]
机构
[1] Santa Maria Misericordia Univ Hosp, Clin Neurol Unit, I-33100 Udine, Italy
[2] Santa Maria Misericordia Univ Hosp, Neurol Unit, I-33100 Udine, Italy
[3] Univ Udine, Dept Med DMED, Neurol Unit, I-33100 Udine, Italy
[4] Univ Udine, Dept Med DMED, Immunol, I-33100 Udine, Italy
关键词
multiple sclerosis; Ocrelizumab; Rituximab; anti-CD20; NK cells;
D O I
10.3390/ph17020150
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Recently, research on the pathogenesis of multiple sclerosis (MS) has focused on the role of B lymphocytes and the possibility of using specific drugs, such as Ocrelizumab and Rituximab, directed toward these cells to reduce inflammation and to slow disease progression. Objective: We aimed to evaluate the effect of Ocrelizumab/Rituximab on laboratory immune parameters and identify the predictors of treatment responses. Methods: A retrospective single-center study was conducted among patients who received infusion therapy with an anti-CD20 drug to treat MS. Results: A total of 64 patients met the inclusion criteria, with 277 total cycles of therapy studied. Compared with the baseline values, anti-CD20 infusions resulted in absolute-value and percentage decreases in B lymphocyte levels and increased the absolute and percentage levels of NK cells 3 and 5 months after therapy (p < 0.001). After multivariate logistic regression analysis, a reduced percentage level of NK cells 3 months after infusion could predict disease activity 6 months after Ocrelizumab/Rituximab administration (p = 0.041). Conclusions: Lower percentage levels of NK cells 3 months after anti-CD20 infusion correlate with the presence of disease activity 6 months after therapy, confirming a possible protective role of NK cells in MS.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
    Jeffrey M. Gelfand
    Bruce A. C. Cree
    Stephen L. Hauser
    Neurotherapeutics, 2017, 14 : 835 - 841
  • [42] Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
    Gelfand, Jeffrey M.
    Cree, Bruce A. C.
    Hauser, Stephen L.
    NEUROTHERAPEUTICS, 2017, 14 (04) : 835 - 841
  • [43] Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis
    del Canto, Adolfo
    Carcamo, Claudia
    Garcia, Lorena
    Aylwin, Ester
    Jurgensen-Heinrich, Lukas
    Guzman-Carcamo, Ignacio
    de la Barra, Juan
    Gutierrez-Calquin, Leticia
    Barrera-Hormazabal, Antonia
    Cruz, Juan Pablo
    Bravo, Sebastian
    Pelayo, Carolina
    Soler, Bernardita
    Uribe-San-Martin, Reinaldo
    Ciampi, Ethel
    MULTIPLE SCLEROSIS JOURNAL, 2025, : 444 - 454
  • [44] Higher minor hemoglobin A2 levels in multiple sclerosis patients correlate with lesser disease severity
    Ozcan, Muhammed Emin
    Ince, Bahri
    Karadeli, Hasan Huseyin
    Gedikbasi, Asuman
    Asil, Talip
    Altinoz, Meric A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 2033 - 2038
  • [45] Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
    Prockl, Victoria
    Nickel, Florian T.
    Utz, Kathrin S.
    Froehlich, Kilian
    Engelhorn, Tobias
    Hilz, Max-Josef
    Lee, De-Hyung
    Linker, Ralf A.
    Huhn, Konstantin
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
  • [46] Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis
    Sawai, Setsu
    Umemura, Hiroshi
    Mori, Masahiro
    Satoh, Mamoru
    Hayakawa, Sei
    Kodera, Yoshio
    Tomonaga, Takeshi
    Kuwabara, Satoshi
    Nomura, Fumio
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 218 (1-2) : 112 - 115
  • [47] Serum uric acid levels in multiple sclerosis patients inversely correlate with disability
    A. L. Guerrero
    F. Gutiérrez
    F. Iglesias
    J. Martín-Polo
    S. Merino
    J. I. Martín-Serradilla
    E. Laherrán
    M. A. Tejero
    Neurological Sciences, 2011, 32 : 347 - 350
  • [48] Serum uric acid levels in multiple sclerosis patients inversely correlate with disability
    Guerrero, A. L.
    Gutierrez, F.
    Iglesias, F.
    Martin-Polo, J.
    Merino, S.
    Martin-Serradilla, J. I.
    Laherran, E.
    Tejero, M. A.
    NEUROLOGICAL SCIENCES, 2011, 32 (02) : 347 - 350
  • [49] Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients
    Szilasiova, Jarmila
    Rosenberger, Jaroslav
    Fedicova, Miriam
    Mikula, Pavol
    Urban, Peter
    Gdovinova, Zuzana
    Vitkova, Marianna
    Hanes, Jozef
    Stevens, Eva
    EUROPEAN NEUROLOGY, 2021, 84 (04) : 272 - 279
  • [50] Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
    Schuckmann, Aaron
    Steffen, Falk
    Zipp, Frauke
    Bittner, Stefan
    Pape, Katrin
    MED, 2023, 4 (06): : 361 - +